The FDA finalized label changes removing the boxed warnings about cardiovascular disease, breast cancer and probable dementia from six menopausal hormone replacement therapies (HRTs). The agency reviewed submissions from manufacturers and acted after a panel and literature assessments supporting narrower risk statements. Commissioner Marty Makary said the move aims to increase access and reduce undue fear among women seeking treatment for vasomotor symptoms. Medical societies offered cautious support while underscoring the need for individualized risk communication. The relabeling will alter prescribing conversations and may shift utilization patterns in menopause care.